Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects.

Journal of Clinical Psychopharmacology
Clemens MuehlanJasper Dingemanse

Abstract

Daridorexant is a dual orexin receptor antagonist in development for the treatment of sleep disorders. Thus far, it has not yet been studied in Japanese subjects. Study objectives were to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of single- and multiple-dose administration of daridorexant in healthy Caucasian and Japanese subjects. This was a double-blind, placebo-controlled, randomized study. Subjects received once-daily doses of daridorexant (25 or 50 mg) or placebo for 5 days. Pharmacokinetics and safety were investigated using standard assessments. To assess PD effects, a battery of tests (saccadic peak velocity, body sway, adaptive tracking performance, and visual analog scales for alertness, mood, and calmness), known to be sensitive to sleep-promoting drugs was used. On day 1, PK variables were similar between Caucasian and Japanese subjects. On day 5, slight accumulation occurred in Japanese but not in Caucasian subjects, resulting in a higher maximum concentration (1403 vs 1006 ng/mL) and area under the curve (8256 vs 6306 ng·h/mL) at a dose of 50 mg, whereas values for time to maximum concentration and half-life were similar. Daridorexant dose-dependently reduced vigilance, attention, visuo...Continue Reading

References

Aug 1, 1980·Clinical Pharmacology and Therapeutics·R SpectorM M Ghoneim
Jan 18, 2003·Vascular Pharmacology·Michel DemeuleRichard Béliveau
Sep 3, 2004·Journal of Clinical Pharmacology·Kiman KimHartmut Derendorf
Nov 25, 2004·Journal of Sleep Research·Christian Sturzenegger, Claudio L Bassetti
Jan 30, 2007·Nature Medicine·Catherine Brisbare-RochFrançois Jenck
Feb 20, 2007·CNS & Neurological Disorders Drug Targets·Gary K Zammit
Mar 1, 2008·Journal of Psychopharmacology·Ib ChaudhryN Husain
Apr 9, 2010·Clinical Pharmacology and Therapeutics·P HoeverJ Dingemanse
Aug 9, 2012·Future Cardiology·Larisa H Cavallari, Minoli A Perera
Nov 20, 2016·Annual Review of Pharmacology and Toxicology·Paul J ColemanJohn J Renger
Dec 7, 2016·Nature and Science of Sleep·Chin Moi ChowKatharine Steinbeck
Feb 6, 2017·Sleep Medicine Clinics·Michael A Grandner
Feb 24, 2017·Neuron·Thomas E ScammellJonathan O Lipton
Jul 1, 2017·The Journal of Pharmacology and Experimental Therapeutics·Alexander TreiberFrancois Jenck
Feb 16, 2018·Clinical Pharmacology and Therapeutics·Clemens MuehlanJasper Dingemanse
Jun 9, 2018·Journal of Central Nervous System Disease·David N NeubauerJaime M Monti
Oct 5, 2018·European Journal of Clinical Pharmacology·Marie-Laure BoofJasper Dingemanse
Jun 22, 2019·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Clemens MuehlanJasper Dingemanse

❮ Previous
Next ❯

Citations

Jul 1, 2020·Clinical and Experimental Pharmacology & Physiology·Isabelle ZenklusenJasper Dingemanse
Sep 10, 2020·Expert Opinion on Drug Metabolism & Toxicology·Clemens MuehlanJasper Dingemanse
Jun 15, 2021·Clinical and Translational Science·Benjamin BergerJasper Dingemanse

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.